We serve as a link between scientists and the society, by bridging the gap between CRG early stage research and the market

ANABEL SANZ: Head of TBDO

We translate new scientific knowledge into benefits for health and value for society

LUIS SERRANO: CRG Director

Our research has the potential to improve people’s lives

MARA DIERSSEN: Head of the “Cellular and Systems Neurobiology” Group

For CRG Community & Inventors

Research activities often lead to discoveries and inventions, and to the development of new tools and materials that may benefit society. TBDO helps CRG scientists realize the potential of their cutting-edge research, promoting the transition of their discoveries and ideas from the lab into real-life benefits.

Learn more

For Industry & Investors

CRG offers a variety of cutting-edge avenues for collaboration. TBDO is committed to working with industry partners and investors for the progression of CRG research into benefits for society. Our team facilitates this translation by fostering relationships that bridge the gap between early stage technologies and commercialization.

Learn more

For Entrepreneurs

CRG is a globally recognized leader in knowledge creation. TBDO nurtures this fertile environment by providing its community with the knowledge, support and networking opportunities needed to develop an entrepreneurial mindset to make social impact.

Learn more

The Technology & Business Development Process at CRG

Learn more about the Technology Transfer Process at CRG through our FAQs

20 June 2019

TBDO Sessions Edgardo Ferran

20/06/201916:00CHARLES DARWINTBDO SessionsEdgardo FerranEMBL_EBI visiting scientist/CRG scientific collaboratorAn introduction to Pharma Industry and EBI Industry ProgrammeHost: Montava Guill, EsterAbstract:Why do we need pharma industry? What is the current business model of the big pharma? How drug discovery and development is done in these companies? How many new medicines are approved each year by the regulatory agencies? How the companies communicate their financial and clinical results? What a pharma clinical pipeline looks like? Which strategies do they follow under the risk of a patent cliff? Why pharma companies merge or buy a concurrent company? Which are the scientific subjects that currently interest the big pharma? How...

20 June 2019

a href=https://www.crg.eu/en/event/tbdo-sessions-edgardo-ferranTBDO Sessions Edgardo Ferran/a

pspan class=body_120/06/2019/spanspan class=body_216:00/spanspan class=body_3CHARLES DARWIN/spanspan class=body_4TBDO Sessions/spanspan class=body_5Edgardo Ferran/spanspan class=body_6EMBL_EBI visiting scientist/CRG scientific collaborator/spanspan class=body_7An introduction to Pharma Industry and EBI Industry Programme/spanspan class=body_8Host: Montava Guill, Ester/spanspan class=body_9Abstract:/spanWhy do we need pharma industry? What is the current business model of the big pharma? How drug discovery and development is done in these companies? How many new medicines are approved each year by the regulatory agencies? How the companies communicate their financial and clinical results? What a pharma clinical pipeline looks like? Which strategies do they follow under the risk of a patent cliff? Why pharma companies merge or buy a concurrent company? Which are the scientific subjects that currently interest the big pharma? How.../p

10 September 2018

Two CRG projects have been awarded ERC Proof of Concept grants

IMPACCT and MycoVAP projects both will receive ERC PoC grants to explore potential clinical applications of their recent results on breast cancer and pneumonia respectively.

More news